Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.

Authors

null

James M. G. Larkin

The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

James M. G. Larkin , Michele Del Vecchio , Paolo Antonio Ascierto , Jacob Schachter , Claus Garbe , Bart Neyns , Mario Mandala , Paul Lorigan , Wilson H Miller , Alexander David Guminski , Carola Berking , Piotr Rutkowski , Paola Queirolo , Axel Hauschild , Ana Maria Arance , Michael Paul Brown , Lada Mitchell , Maria Luisa Veronese , Christian U. Blank

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT01307397

Citation

J Clin Oncol 31, 2013 (suppl; abstr 9046)

DOI

10.1200/jco.2013.31.15_suppl.9046

Abstract #

9046

Poster Bd #

45A

Abstract Disclosures